Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

Wake, B., Hyde, C., Bryan, S., Barton, P. M., Song, F., Fry-Smith, A. and Davenport, C. (2002) Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technology Assessment, 6 (3). pp. 1-85. ISSN 2046-4924

Full text not available from this repository. (Request a copy)

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health Faculty of Medicine and Health Sciences > Research Centres > Population Health
Depositing User:	EPrints Services
Date Deposited:	25 Nov 2010 11:11
Last Modified:	24 Sep 2024 10:20
URI:	https://ueaeprints.uea.ac.uk/id/eprint/13890
DOI:	10.3310/hta6030

Actions (login required)

View Item